Investors Are Urged to Lead Semler Scientific Securities Fraud Lawsuit

Semler Scientific Securities Fraud Lawsuit: Important Update for Investors

The Rosen Law Firm, renowned for its advocacy in investor rights, is highlighting a pressing opportunity for investors who purchased securities from Semler Scientific, Inc. (NASDAQ: SMLR) between March 10, 2021, and April 15, 2025. This communication serves as a reminder of the impending deadline of October 28, 2025, to assume a lead plaintiff role in the class action lawsuit initiated by the firm.

Overview of the Situation

Investors who acquired shares of Semler Scientific during the specified period may be eligible for compensation without incurring out-of-pocket expenses, thanks to the firm's contingency fee arrangements. Those interested in participating in the class action are encouraged to visit the Rosen Law Firm’s website or reach out to attorney Phillip Kim via phone or email to gather further details about their specific rights and options.

Why This Case Matters

The lawsuit against Semler Scientific arises from allegations that the company made materially false statements and omitted critical information regarding a significant inquiry by the U.S. Department of Justice (DOJ). During the Class Period, it is alleged that Semler did not adequately disclose this investigation into potential violations of the False Claims Act. This misleading information has purportedly led to substantial financial losses for investors when the actual facts emerged, affecting the company's credibility and stock value.

To qualify as a lead plaintiff, an individual must formally apply to the Court by October 28, 2025. A lead plaintiff plays a pivotal role as a representative for other class members, guiding the case and ensuring that the interests of all affected shareholders are adequately represented.

Choosing the Right Legal Counsel

The Rosen Law Firm emphasizes the importance of selecting legal representation with a proven track record in handling securities class actions. Unlike many firms that simply act as intermediaries, Rosen Law Firm’s experienced team actively litigates securities claims, having achieved numerous significant settlements on behalf of investors. Their history of handling large-scale lawsuits, including one of the largest securities class action settlements against a Chinese company, underscores their capability and commitment to investor rights.

In 2019, the firm secured over $438 million for investors, showcasing their advocacy in the field. Attorney Laurence Rosen has earned remarkable recognition in the legal community, being labeled as a Titan of the Plaintiffs' Bar by law360 in 2020.

Details of the Class Action Lawsuit

The press release from the Rosen Law Firm indicates that the lawsuit outlines how the defendants engaged in misleading practices. The firm asserts that by failing to disclose critical information about the DOJ investigation, Semler Scientific caused a cascade of misinformation, ultimately resulting in financial damage to its investors when the reality came to light.

For those who wish to engage with this class action lawsuit but do not desire to take on the lead plaintiff responsibility, it is important to note that remaining an absent class member is also a viable option. In such cases, an investor’s eligibility to participate in any future recovery is unaffected by one's decision to serve as a lead plaintiff.

How to Get Involved

To become part of the Semler Scientific class action, interested investors are advised to navigate to Rosen Law Firm's class action form or to connect with the firm through phone at 866-767-3653 or email at [email protected] for further inquiries regarding joining the litigation.

In conclusion, this situation presents a critical moment for Semler Scientific investors. With a robust opportunity to affect the outcome of this lawsuit, it is crucial to act swiftly and make informed decisions regarding participation. Follow the Rosen Law Firm on social media platforms like LinkedIn, Twitter, and Facebook for ongoing updates and developments.

Disclaimer: This communication should not be considered as legal advice but rather as an informational resource for impacted shareholders. Past outcomes do not guarantee similar results in future cases.